100 related articles for article (PubMed ID: 2613077)
1. [Results of the "light pill" action].
Gerstner GJ; Kunze M
Gynakol Rundsch; 1989; 29 Suppl 2():469-71. PubMed ID: 2613077
[No Abstract] [Full Text] [Related]
2. [Does an increase in endogenous estradiol in treatment with low-dose ovulation inhibitors signify increased risk?].
Kuhl H
Geburtshilfe Frauenheilkd; 1991 Jun; 51(6):492. PubMed ID: 1889734
[No Abstract] [Full Text] [Related]
3. [Oral contraceptives: 30 vs 20 micrograms of ethinyl estradiol (EE)].
Urdinola J
Adv Contracept; 1994 Jul; 10 Suppl 1():41-9. PubMed ID: 7839871
[No Abstract] [Full Text] [Related]
4. [Clinical study of low-dose oral contraceptives (with low-doses of ethinyl estradiol), widely used in practice].
Nalbanski B; Tsekova K; Ivanov S
Akush Ginekol (Sofiia); 2001; 41 Suppl 4():20-3. PubMed ID: 11519317
[No Abstract] [Full Text] [Related]
5. [Low dose p-pills, Gynatrol and Mikrogyn].
Falck Larsen J
Ugeskr Laeger; 1976 Sep; 138(40):2446-7. PubMed ID: 969002
[No Abstract] [Full Text] [Related]
6. [Modern extremely low dose oral contraception with lindynette 20].
Radinski G
Akush Ginekol (Sofiia); 2008; 47 Suppl 2():40-2. PubMed ID: 19504706
[No Abstract] [Full Text] [Related]
7. [Proper education for the patient! Risk of thromboembolism with oral contraception].
Wenderlein JM
MMW Fortschr Med; 2000 Feb; 142(7):38-9. PubMed ID: 10832333
[No Abstract] [Full Text] [Related]
8. Oral contraceptives and thromboembolism.
Med Lett Drugs Ther; 1972 Aug; 14(17):61-2. PubMed ID: 4567564
[No Abstract] [Full Text] [Related]
9. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism].
Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G
Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773
[No Abstract] [Full Text] [Related]
10. Missed contraceptive pills and the critical pill-free interval.
Mansour D; Fraser IS
Lancet; 2005 May 14-20; 365(9472):1670-1. PubMed ID: 15894085
[No Abstract] [Full Text] [Related]
11. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives.
Norris LA; Bonnar J
Thromb Haemost; 1994 Dec; 72(6):926-30. PubMed ID: 7740465
[TBL] [Abstract][Full Text] [Related]
12. Use of an oral contraceptive containing drospirenone in an extended regimen.
Sillem M; Schneidereit R; Heithecker R; Mueck AO
Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of an extended-regimen oral contraception utilizing low-dose ethinyl estradiol.
Anderson FD
Contraception; 2006 Oct; 74(4):355. PubMed ID: 16982247
[No Abstract] [Full Text] [Related]
14. [Hormones and hemostasis].
Winkler UH
Geburtshilfe Frauenheilkd; 1994 Mar; 54(3):M39-42. PubMed ID: 8188004
[No Abstract] [Full Text] [Related]
15. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
Cremer P; Vekemans M
Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
[No Abstract] [Full Text] [Related]
16. Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities.
Jendryczko A; Tomala J; Janosz P
Zentralbl Gynakol; 1993; 115(11):469-72. PubMed ID: 8296490
[TBL] [Abstract][Full Text] [Related]
17. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
Edelman AB; Koontz SL; Nichols MD; Jensen JT
Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938
[TBL] [Abstract][Full Text] [Related]
18. [Is it really necessary to discontinue hormonal contraceptives before carrying out a planned operation?].
Zentralbl Gynakol; 1989; 111(11):771-80. PubMed ID: 2781890
[No Abstract] [Full Text] [Related]
19. Changes in alpha 1-antitrypsin (AAT) and alpha 2-macroglobulin serum concentrations during treatment with oral estro-progestogens.
Paternoster D; Maggino T; Valente S; Pengo V; Ongaro G
Quad Sclavo Diagn; 1982 Jun; 18(2):132-9. PubMed ID: 6188185
[No Abstract] [Full Text] [Related]
20. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
